Gilead Sciences, Inc., Petitioner v. United States ex rel. Jeffrey Campie, et al.
Case Number:
17-936
Court:
Nature of Suit:
Firms
Companies
- ConocoPhillips Co.
- CTIA
- Gilead Sciences Inc.
- Pharmaceutical Research & Manufacturers of America
- Washington Legal Foundation
Sectors & Industries:
-
January 07, 2019
High Court Denies Gilead FCA Case After DOJ Thumbs-Down
The U.S. Supreme Court on Monday chose not to hear a prominent False Claims Act case linking Gilead Sciences Inc. to sketchy drug manufacturing, a move that follows the U.S. Department of Justice's bombshell vow to end the whistleblower-led litigation.
-
January 01, 2019
Gov't Contracts Cases To Watch In 2019
A U.S. Supreme Court case involving statutes of limitations on False Claims Act allegations, one of a number of important FCA issues the high court may soon tackle, will join a high-profile challenge to a $10 billion U.S. Department of Defense cloud deal as one of several prominent cases for government contractors to watch in 2019.
-
January 01, 2019
Health Care Cases To Watch In 2019
The health care industry in 2019 will watch with bated breath as a guillotine hangs over the Affordable Care Act, historic litigation involving the opioid crisis heads to trial and the murky meaning of a landmark False Claims Act decision becomes clearer. Here, Law360 gets attorneys up to speed on must-watch cases in the year ahead.
-
January 01, 2019
Life Sciences Cases To Watch In 2019
The life sciences industry will be keeping an eye on courtrooms around the country in 2019, watching to see how the U.S. Supreme Court decides a legal battle over patent protection for drugs and monitoring the fallout from federal prosecutors' decision to spike a False Claims Act case. Here are seven cases life sciences attorneys say they'll be following in the coming year.
-
December 20, 2018
Top Gov't Contracts Cases From The 2nd Half Of 2018
Courts have handed down a number of important decisions for federal contractors in the second half of 2018, with the Federal Circuit having been particularly busy, addressing issues ranging from an important federal preference law to how specific agency corrective action must be.
-
December 19, 2018
Relators Double Down In Gilead FCA Case After DOJ Threat
Nearly three weeks after the U.S. Department of Justice torpedoed high-stakes False Claims Act litigation against Gilead Sciences Inc., the whistleblowers on Wednesday reupped their plea for the U.S. Supreme Court to turn down the drugmaker's appeal but didn't address the government's looming threat to end the case no matter what.
-
December 04, 2018
5 Key Questions As DOJ Torpedoes Gilead FCA Suit
The U.S. Department of Justice’s bombshell move to let Gilead Sciences Inc. escape a multibillion-dollar False Claims Act suit is sparking speculation about the DOJ’s motivations and the implications for similar suits alleging regulatory violations. Here are five important questions raised by the DOJ’s move.
-
November 30, 2018
DOJ Will Nuke Gilead FCA Suit, Supreme Court Hears
In a stunning move, the U.S. Department of Justice on Friday told the U.S. Supreme Court that it wants to terminate a closely watched whistleblower suit against Gilead Sciences Inc., asserting that the False Claims Act case is "not in the public interest."
-
September 28, 2018
5 High Court Battles Health Cos. Should Keep An Eye On
Health care companies will be keeping an eagle eye on potential blockbuster cases after the U.S. Supreme Court's new term gets underway Monday, including fights over patient privacy, Medicare reimbursement, False Claims Act liability and abortion rights. Here, Law360 summarizes five important battles to watch.
-
August 31, 2018
Pharma Cases To Watch In 2018's Home Stretch
Drugmakers in the closing months of 2018 may see pivotal rulings on novel efforts to hamstring rival medicines, escalating drama in multidistrict litigation over the opioid epidemic, and opening salvos in False Claims Act and drug-pricing fights at the U.S. Supreme Court. Here, Law360 summarizes key cases to watch.